This Article Full Text Full Text (PDF) Other Versions of this Article: AAC.00716-07v1 51/12/4284    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Reddy, Y. S. Articles by Symonds, W. T. Search for Related Content PubMed PubMed Citation Articles by Reddy, Y. S. Articles by Symonds, W. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, December 2007, p. 4284-4289, Vol. 51, No. 12
0066-4804/07/$08.00+0     doi:10.1128/AAC.00716-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Safety and Pharmacokinetics of GSK364735, a Human Immunodeficiency Virus Type 1 Integrase Inhibitor, following Single and Repeated Administration in Healthy Adult Subjects

Y. Sunila Reddy,^1, Sherene S. Min,^1* Julie Borland,¹ Ivy Song,¹ Jiang Lin,¹ Sandra Palleja,² and William T. Symonds^1,

GlaxoSmithKline, Research Triangle Park, North Carolina Shionogi USA, Inc., Florham Park, New Jersey

Received 1 June 2007/ Returned for modification 23 July 2007/ Accepted 30 September 2007

GSK364735 is a human immunodeficiency virus (HIV) integrase strand transfer inhibitor with potent in vitro antiviral activity. This study was a double-blind, randomized, placebo-controlled, dose escalation, phase I study to assess single- and repeated-dose safety, tolerability, pharmacokinetics (PK), and food effect of GSK364735 in healthy subjects. In part A, three alternating cohorts of 10 subjects (8 receiving the active drug and 2 receiving a placebo) received single doses of 50 to 400 mg while fasting or 200 mg and 400 mg coadministered with food. In part B, five cohorts received repeated doses of 100 to 600 mg daily coadministered with food for 8 days. Safety was assessed throughout the study. Serial blood samples were analyzed for GSK364735 plasma concentrations using a validated high-performance liquid chromatography-tandem mass spectrometry assay. PK parameters were estimated using noncompartmental methods. Seventy-nine (30 in part A and 49 in part B) subjects were enrolled and received GSK364735 or placebo. GSK364735 was readily absorbed following oral dose administration, with the maximum concentration achieved between 0.75 to 5.0 h postdose. GSK364735 exposure increased less than dose proportionally, demonstrated wide variability, and appeared to reach a plateau at 100- to 200-mg doses. Food increased GSK364735 exposure by 28 to 91%. GSK364735 was safe and well tolerated after single- and repeated-dose administration. No serious or severe adverse events (AEs) or AEs leading to withdrawal and few drug-related AEs were reported. Despite solubility-limited absorption, GSK364735 exceeded therapeutic trough concentrations for the majority of doses studied. The PK and safety profile supported the continued investigation of GSK364735 in HIV-infected subjects.

Published ahead of print on 8 October 2007.

Present address: Gilead Sciences, Inc., Foster City, CA.

Present address: Pharmasset, Inc., Princeton, NJ.